hims glp 1 results expansion may not come in time for risky GLP-1 business Hims Tumbles 19% After CEO

Sardou, H

10.1073/pnas.1921223117 240 TanT.BeharyP.TharakanG.MinnionJ.Al-NajimW.AlbrechtsenN

Int J Mol Sci (2023) 24(11):9166

The company has a registered Delaware LLC, a published physical address (131 Continental Dr, Ste 305, Newark, DE 19713), published contact information, and a substantial customer base reflected across multiple independent review platforms

Orforglipron 36 mg lowered HbA1c 0.33% more than semaglutide 14 mg

While studies are currently exploring the possibilities of preventing these side effects, there are currently no GLP-1 drugs on the market that do not have the potential to cause these side effects